Core Viewpoint - The company has not yet developed any technology or reserves in the solid-state battery sector but is closely monitoring market trends [2] Group 1: Company Developments - The company has stated that its hydrogenated nitrile butadiene rubber (HNBR) products have the potential to replace PVDF as a leading adhesive in the emerging battery industry [2] - The construction and installation of the industrialization project for HNBR at the company's subsidiary, Binzhou Kaitai, have been completed, and the project is currently in the debugging and finalization phase [2] - The successful implementation of this project is expected to provide a solid foundation for the company's future development in high-end new materials and the transformation of new catalytic technologies [2]

Group 1 - The company stated that its catalyst products can be used in the development of innovative drugs, pharmaceutical intermediates, and active pharmaceutical ingredients [2] - By the first half of 2025, the revenue from the pharmaceutical sector is expected to account for 40.51% of the company's total catalyst income [2]

Group 1 - The core viewpoint of the article is that Kaili New Materials (688269.SH) has developed catalyst products that can be utilized in the research and development of innovative drugs, as well as in the production of pharmaceutical intermediates and active pharmaceutical ingredients [1] - By the first half of 2025, the revenue from the pharmaceutical sector for the company’s catalyst products is expected to account for 40.51% of total revenue [1]

Core Viewpoint - The company focuses on catalyst preparation and application technology, while gradually expanding into basic chemicals and environmental new energy sectors [1] Group 1 - The company's main business revolves around catalyst preparation and application technology [1] - The company is deepening its efforts in the fine chemical field [1] - The company has not yet developed relevant technology layout and reserves in the solid-state battery field [1] Group 2 - The company is continuously monitoring and keeping pace with market development trends [1]

财报季，社保基金持股动向曝光！二季度末社保基金共现身12只个股前十大流通股东榜，新进2只，增 持6只。 证券时报·数据宝统计显示，社保基金最新出现在12只科创板股前十大流通股东名单中，合计持股量 4942.64万股，期末持股市值合计24.11亿元。持股变动显示，新进2只，增持6只，减持3只，1只股持股 量保持不变。 社保基金持有科创板股中，从前十大流通股东名单中社保基金家数来看，南微医学、凯立新材等2只股 有3家社保基金集中现身，持股量分别为917.85万股、636.42万股。 市场表现方面，获社保基金持有的科创板股7月以来平均上涨29.42%。从具体个股看，鼎通科技累计涨 幅92.20%，表现最好，苑东生物、南微医学等分别上涨52.36%、41.13%位居其后。从具体个股看，鼎 通科技累计涨幅92.20%，表现最好，苑东生物、南微医学等分别上涨52.36%、41.13%位居其后。（数 据宝） | 代码 | 简称 | 社保基金家 | | 社保基金持股量（万 | 环比 | 占流通股比例 | 持股市值（万 | | --- | --- | --- | --- | --- | --- | --- | --- | | ...

Group 1 - The core viewpoint of the report is that despite a decline in quarterly revenue, the company's profit has increased on a month-on-month basis, and the gross profit margin has reached a three-year high [2] - The pharmaceutical and basic chemical sales have experienced rapid growth, and high-priced sales have driven revenue growth in the first half of the year [2] - The company has made significant progress in catalyst research and development, with breakthroughs in basic chemical projects and the HNBR entering trial operation [2]

Group 1: Daotong Technology - Daotong Technology is developing an end-to-end payment solution in the AI + charging business, supporting multiple payment methods and exploring stablecoin payments and RW financing [1] - The AI and software business operates on a subscription model, providing various value-added services to enhance software revenue and renewal rates [1] - The growth of the TPMS business is driven by policy benefits and market demand, with significant global aftermarket replacement demand [1] - The AI + inspection business has been implemented in oilfield inspections, achieving a fully autonomous process closure and cluster collaborative response [1] Group 2: Kaili New Materials - In Q2, Kaili New Materials experienced significant profit growth, but revenue declined due to changes in business structure [2] - In the first half of the year, the revenue breakdown showed that the fine chemicals sector accounted for 70.48%, basic chemicals for 25.35%, and environmental new energy for 2.90% [2] - Sales of mercury-free PVC catalysts reached 258 tons, with 366 tons in hand orders, and sales of mercury-free PVC catalysts increased by 113.22% [2] - The high-performance platinum-based dehydrogenation catalyst is in batch trial production, while the hydrogenated nitrile rubber project is in the debugging phase, with applications in oilfields and the automotive industry [2] - The pharmaceutical segment saw a sales increase of 49.26%, with expectations for continued growth in the global pharmaceutical market and R&D service demand [2] - The company plans to optimize resources by deregistering Kaili Platinum, which has not commenced operations [2] - The fair value change loss is primarily due to the initiation of gold leasing business [2]

Investment Rating - The investment rating for the company is "Buy" with a target price not specified [5]. Core Views - The company achieved a revenue of 1.014 billion yuan in the first half of 2025, representing a year-on-year increase of 24.9%, and a net profit attributable to the parent company of 61.2 million yuan, up 30.8% year-on-year [1]. - Despite a decline in revenue in Q2 2025, the net profit increased significantly by 79.4% compared to Q1 2025, with a gross margin reaching 18.26%, the highest in nearly three years [1][2]. - The growth in revenue is primarily driven by a 122.33% increase in catalyst product sales, particularly in the pharmaceutical and basic chemical sectors, which saw sales growth of 49.26% and 185.54% respectively [2]. - The company has made significant advancements in catalyst research and development, with 23 new invention patents filed in the first half of 2025, and several projects in the basic chemical sector achieving breakthroughs [3]. Financial Data and Forecast - The company is projected to achieve net profits of 174 million yuan, 241 million yuan, and 404 million yuan for the years 2025, 2026, and 2027 respectively, reflecting a positive growth trajectory [4][3]. - The expected revenue for 2025 is 2.266 billion yuan, with a growth rate of 34.33% compared to 2024 [4]. - The company's earnings per share (EPS) is forecasted to be 1.33 yuan in 2025, increasing to 3.09 yuan by 2027 [4]. Market Position and Competitive Advantage - The company has strengthened its market position in the pharmaceutical sector due to increased demand from core customers and enhanced competitiveness, leading to a rise in market share [2]. - In the basic chemical sector, the company has achieved a 113.22% increase in sales of mercury-free PVC catalysts, supported by the launch of multiple new products [2]. - The environmental and new energy sectors have also seen remarkable growth, with sales increasing by 1497.06% due to advancements in hydrogen energy catalysts and partnerships with leading hydrogen production companies [2].

Core Insights - Pension funds have emerged as significant shareholders in several companies, indicating a growing interest in these stocks by institutional investors [1] Group 1: Company Holdings - Shengyi Electronics is now the 10th largest circulating shareholder of the pension fund, holding 5.33 million shares, which accounts for 0.64% of the circulating shares [1] - Rongzhi Rixin is the 4th largest circulating shareholder of the pension fund, with 3.5 million shares, representing 4.04% of the circulating shares [1] - Kaili New Materials is also the 4th largest circulating shareholder of the pension fund, holding 1.9967 million shares, which is 1.53% of the circulating shares [1] Group 2: Pension Fund Stock Data - Shengyi Electronics (688183) has a pension fund holding of 5.33 million shares, newly entered, with a market value of approximately 27.31 million yuan [1] - Rongzhi Rixin (688768) has a pension fund holding of 3.5 million shares, a decrease of 5.41% from the previous period, with a market value of about 15.54 million yuan [1] - Kaili New Materials (688269) maintains a pension fund holding of 1.9967 million shares, unchanged from the previous period, with a market value of around 6.63 million yuan [1]

Core Viewpoint - The company reported strong financial performance in H1 2025, driven by increased sales of catalyst products and structural changes in its business model [1] Group 1: Financial Performance - In H1 2025, the company achieved revenue, net profit attributable to shareholders, and net profit excluding non-recurring gains and losses of 1.014 billion, 61 million, and 63 million yuan respectively, representing year-on-year increases of 24.86%, 30.83%, and 48.74% [1] - In Q2 2025, the company recorded revenue, net profit attributable to shareholders, and net profit excluding non-recurring gains and losses of 389 million, 39 million, and 40 million yuan respectively, with year-on-year changes of -23.42%, +11.38%, and +15.47% [1] Group 2: Business Segments - The sales volume in the basic chemical sector increased by 185.5% year-on-year, primarily due to a 113.2% increase in sales of mercury-free PVC catalysts, along with the introduction of multiple basic chemical catalysts to the market [1] - The pharmaceutical segment saw a sales increase of 49.3% year-on-year, driven by increased demand from core customers and an improvement in market share [1] - The environmental and new energy segment experienced a staggering 1497.1% increase in sales year-on-year, attributed to significant progress in hydrogen catalysts and partnerships with leading companies in water electrolysis hydrogen production [1] Group 3: Future Outlook - The company is expected to maintain an upward trend in its fundamentals, with significant breakthroughs in key customer orders for PVC products anticipated in the second half of 2024 [2] - The company has a backlog of 461 tons of orders for PVC products as of the end of Q1 2025, which is expected to support high growth in sales and revenue for the basic chemical sector throughout the year [2] - The HNBR (hydrogenated nitrile butadiene rubber) industrialization project is expected to launch in the second half of 2025, which could lead to a significant improvement in production efficiency and product quality, positioning the company as a leader in the domestic high-end HNBR market [2] Group 4: Profit Forecast and Investment Recommendation - The company is projected to achieve net profits attributable to shareholders of 170 million, 236 million, and 268 million yuan for 2025-2027, representing year-on-year growth rates of 83.51%, 38.66%, and 13.67% respectively [3] - The current price-to-earnings ratios corresponding to these profit forecasts are 30.8, 22.2, and 19.5 times [3] - The company is expected to exhibit strong performance due to rising prices of key raw materials, increased production in the basic chemical sector, and a recovery in the pharmaceutical sector, leading to a favorable profit growth outlook [3]